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Abstract
Background—Our objective was to study the impact of foot complications on 10 year mortality 
independent of other demographic and biological risk factors in a racially and socioeconomically 
diverse managed care population with access to high-quality medical care.
Methods—We studied 6,992 patients with diabetes in Translating Research Into Action for 
Diabetes (TRIAD), a prospective observational study of diabetes care in managed care. Foot 
complications were assessed using administrative claims data. The National Death Index was 
searched for deaths over 10 years of followup (2000–2009).
Results—Charcot neuroosteoarthropathy (CN) and diabetic foot ulcer with debridement (DFU) 
were associated with an increased risk of mortality; however, the associations were not significant 
in fully adjusted models. Lower extremity amputation (LEA) was associated with an increased risk 
of mortality in both unadjusted (HR 3.21, 95% CI 2.50–4.12) and fully adjusted models (HR 1.84, 
95% CI 1.28–2.63). When we examined the associations between LEA and mortality stratified by 
sex and race, risk was increased in men (HR 1.96, 95% CI 1.25–3.07), Hispanics (HR 5.17, 95% 
CI 1.48–18.01), and Whites (HR 2.18, 95% CI 1.37–3.47). In sensitivity analyses, minor LEA 
tended to increase the risk of mortality (HR 1.48, 95% CI 0.92–2.40) and major LEA was 
associated with a significantly higher risk of death at 10 years (HR 1.89, 95% CI 1.18–3.01).
Conclusions—In this managed care population with access to high-quality medical care, LEA 
remained a robust independent predictor of mortality. The association was strongest in men and 
differed by race.
Introduction
Diabetes-related foot complications have a substantial impact on morbidity, mortality, and 
health care expenditures (1–2). Charcot neuroosteoarthropathy (CN) (3), foot ulceration 
(DFU) (4–5), and lower extremity amputation (LEA) (4–6) have all been associated with 
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mortality. It is not clear what the independent contribution of each of these complications is 
to all cause mortality in people with diabetes.
Identification of patients with diabetes with feet at risk, combined with preventive care, can 
prevent LEA, and improved cardiovascular risk factor management can improve long-term 
survival (7–9). Patients with diabetes receiving care from managed care organizations have 
access to preventive care and receive very good diabetes-related processes and intermediate 
outcomes of care (10). As a result, racial and ethnic minorities with diabetes receiving care 
through managed care organizations appear to have lower rates of LEA than similar 
populations with less access to care (11–13).
Our objective was to extend those previous studies by examining the impact of foot 
complications on 10 year mortality independent of other demographic and biological risk 
factors in a racially and socioeconomically diverse managed care population. We 
hypothesized that LEA would remain a risk factor for mortality but that the racial and ethnic 
differences in LEA risk observed in studies of populations with less consistent access to 
care, and the impact of LEA on survival, would be attenuated in this managed care 
population with access to high-quality medical care.
Patients and Methods
Study population
Translating Research Into Action for Diabetes (TRIAD) has been described elsewhere (14). 
TRIAD studied a random sample of adults with diabetes enrolled in 10 managed care health 
plans in eight states (California, Hawaii, Indiana, Michigan, New York, New Jersey, 
Pennsylvania, and Texas) that served ~180,000 patients with diabetes. Patients were eligible 
to participate if they were at least 18 years of age, lived in the community, were not 
pregnant, had diabetes for at least one year, spoke either English or Spanish, were 
continuously enrolled in the health plan for at least 18 months, used at least one service 
during that time, and could give informed consent. Institutional review boards reviewed and 
approved the study at each participating site and all participants provided informed consent.
In 2000–2001, we administered a survey by computer-assisted telephone interview or in 
writing by mail. In addition, centrally trained reviewers used standardized methods to 
abstract medical records. Health plan administrative data were collected for 1999 through 
2003. 11,927 people initially consented to participate (69% CASRO response rate) and 
8,820 provided survey and medical record data. The analytic sample for this study included 
participants who had survey and medical record data at baseline and were enrolled at sites 
participating in the 2010–2013 TRIAD Legacy Study (N=6,992). The analytic sample did 
not include data from health plan participants in Hawaii.
Outcomes
Each year, we obtained information on TRIAD decedents using National Death Index (NDI) 
Plus searches (15). Deaths were verified by matching name, date of birth, sex, and social 
security number of the decedent with data supplied by the NDI. The sensitivity of NDI has 
been shown to range from 87% to 98% (16). Different combinations of identifiers excluding 
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social security number correctly identify 83–92% of decedents and 92–99% of living 
individuals, making NDI an accurate means of ascertaining vital status even without social 
security numbers (17). Vital status was determined for all TRIAD Legacy Study participants 
through 31 December 2009.
Primary predictors
We used 1999–2003 health plan administrative data to determine the 3-year period 
prevalence of the three specific foot conditions: Charcot neuroosteoarthropathy (CN), 
diabetic foot ulcer (DFU), and lower extremity amputation (LEA). CN was defined as the 
presence of the International Classification of Diseases, 9th Revision (ICD9), diagnosis code 
713.5 in any inpatient or outpatient records. DFUs were defined using either ICD9 codes 
707.1x or 707.9 in any inpatient or outpatient records. To better define people with active 
DFUs (rather than simply a remote history of DFU), we also required that participants have 
at least one CPT code for debridement (11040, 11041, 11042, 11043, or 11044). LEA was 
defined as the presence of at least one ICD9 procedure code for LEA (84.11, 84.12, 84.13–
84.16, or 84.17–84.19), ICD9 status code for LEA (v49.7), or CPT code for LEA (27590-8, 
27880-9, 28800, 28805, 28810, 28820, or 28825) in any inpatient or outpatient records. We 
defined minor LEA as toe or transmetatarsal amputation and major LEA as any amputation 
below or above the knee. We defined each person as having none or one or more foot 
conditions and examined the occurrence of prevalent conditions using a Venn diagram. We 
then used a hierarchy to place each person with at least one prevalent foot condition into one 
of three mutually exclusive groups: any CN (n=55), DFU (n=205), or LEA with or without 
DFU (n=101).
Covariates
We assessed demographic variables (age, sex, race/ethnicity, education, and income), 
diabetes-specific variables (type of diabetes, duration of diabetes, treatment for diabetes, and 
HbA1c), and other clinical variables (body mass index, systolic blood pressure, low density 
lipoprotein cholesterol, smoking, history of microvascular complications, history of 
macrovascular complications, and Charlson comorbidity index) as possible effect modifiers 
and confounders. Type 1 diabetes was defined by insulin use (without the use or oral 
antidiabetic agents) and age at diagnosis of diabetes < 30 years; all others were defined as 
having type 2 diabetes. Smoking was considered present if the participant reported current 
smoking some days or every day in the past year. The number of comorbidities was defined 
using the Charlson index, a weighted measure of comorbid conditions associated with 
mortality (18).
Statistical Analysis
We described the sample population using means (standard deviation) for continuous 
variables and frequencies for categorical variables. We determined the percent of the sample 
who had died on or before December 31, 2009 and the percent who were still alive. We 
described the distribution of baseline sociodemographic variables and health factors 
stratified by vital status and used student t-tests and chi-square tests for comparisons.
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For each primary predictor of all-cause mortality (CN, DFU, LEA), we constructed a series 
of Cox proportional hazard models. First, we constructed unadjusted models to determine if 
each predictor was associated with the outcome. Second, we constructed fully-adjusted 
models including covariates selected because of their known association with foot 
complications to determine if each primary predictor remained significant even after 
adjustment. At both stages, the Cox proportional hazards models also included a stratum 
statement for health plan/provider group to account for the clustered study design and the 
correlation among participants within health plans and provider groups. All models excluded 
persons with any missing data for any of the covariates in the model.
In sensitivity analyses, we stratified by age, sex, race/ethnicity, and smoking status to 
develop stratum-specific Cox proportional hazards models for the association between LEA 
and mortality. Additional sensitivity analyses included evaluation of any LEA as a predictor 
of mortality (regardless of CN or DFU status because 7 patients with CN also underwent 
LEA) and evaluation of minor (toe or transmetatarsal) and major LEA (below or above the 
knee) as predictors of mortality.
All analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC).
Results
Between 1999 and 2003, 55 (1%) patients had a diagnosis of CN, 205 (3%) had a diagnosis 
of at least one DFU with active debridement, and 101 (2%) had lower extremity amputation 
procedures. There were 6,631 (95%) patients with none of the above foot conditions.
After 10 years of follow-up, 1,956 (29%) participants had died. The mean years until death 
was 7.7 ± 2.3. Those who died were more likely to be older and men, to be of NonHispanic 
White race/ethnicity, and to have lower education and income. They were more likely to 
have type 2 diabetes, to have longer duration of diabetes, and to be treated with insulin. They 
were also more likely to have lower BMI and higher systolic blood pressure, to be smokers, 
and to have histories of retinopathy, nephropathy, neuropathy, hypertension, coronary heart 
disease, congestive heart failure and peripheral vascular disease. Not unsurprising, they were 
also more likely to have higher Charlson indices (Table 1).
Hazard ratios and corresponding 95% confidence intervals for the associations between CN, 
DFU, or LEA and all-cause mortality are shown in Table 2. Relative to those with no foot 
complications, those with LEA had an 84% higher risk of all-cause mortality after adjusting 
for age, sex, race/ethnicity, income, diabetes treatment, HbA1c, BMI, LDL-cholesterol, 
smoking status, history of diabetic nephropathy, myocardial infarction, congestive heart 
failure, and peripheral vascular disease. (Hazard Ratio (HR) 1.84, 95% Confidence Interval 
(CI) 1.28–2.63). Those reporting CN or DFU had higher unadjusted all-cause mortality rates 
compared to those without foot complications but these associations did not remain 
statistically significant after adjustment.
Age, sex, race/ethnicity, and smoking-specific hazard ratios and corresponding 95% 
confidence intervals for the stratum-specific association between LEA and all-cause 
mortality are shown in Table 3. The risk of mortality associated with LEA stratified by age 
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group was significant for every age group. The increased risk of mortality associated with 
LEA was significant in men who had a HR of 1.96 (95% CI 1.25–3.07) but not significant in 
women (HR 1.05 (95% CI 0.50–2.22)). The risk of mortality associated with LEA was 
highest in the Hispanic ethnic group, HR 5.17 (95% CI 1.48–18.01), followed by the 
NonHispanic White group, HR 2.18 (95% CI 1.37–3.47). The race-specific HRs for the 
NonHispanic Black and Other groups were not significantly elevated. The increased risk of 
mortality associated with LEA appeared to be driven by the non-smoking sub-population 
(HR 2.27, 95% CI 1.52–3.39) compared to some or every day smokers (HR 1.92, 95% CI 
0.72–5.16). Since we only inquired about smoking in the past year, it is possible that 
participants with ulcers or LEA were former smokers.
In sensitivity analyses (data not shown), there were 108 people with any LEA with or 
without CN or DFUs. Of the 1956 people who died, 72 (4%) had LEA and of the 5036 
people who remained alive after 10 years, 36 (1%) had LEA (p<0.0001). The 5- and 10-year 
mortality rates for people with LEA were 39% and 67%, respectively. For people without 
LEA, 5- and 10-year mortality rates were 15% and 27%, respectively. Figure 1 presents the 
unadjusted survival curve for any versus no LEA over 10 years of followup. The association 
between any LEA and mortality remained statistically significant in fully-adjusted models 
with a HR of 1.67 (95% CI 1.19–2.35), and the stratum-specific trends were the same as 
those noted above.
The numbers of minor (toe or transmetatarsal) and major (below or above the knee) LEAs 
were equal (N=54 in each category). In multivariate models, minor LEAs were not a 
significant predictor of mortality (HR 1.48, 95% CI 0.92–2.40) but major LEAs were (HR 
1.89, 95% CI 1.18–3.01). Figure 2 presents the unadjusted survival curves for patients 
undergoing minor and major LEAs versus no LEA over the 10 year followup period. It is 
evident from Figure 2 that at 5 years there is not much difference between survival for 
people who had a minor LEA versus no LEA. However, for those who survived past 5 years 
this difference was greater. Survival at 10 years for people who had a minor LEA was 
similar to the survival for people who had a major LEA.
Discussion
CN, DFU, and LEA were all associated with increased all-cause mortality in unadjusted 
analyses. We were not surprised by these findings as foot complications are associated with 
higher levels of pro-inflammatory cytokines, which are associated with mortality. A meta-
analysis has recently described increased mortality associated with chronic elevations of C 
reactive protein (19). CN, DFU, diabetes-related foot infections, and osteomyelitis preceding 
LEA have all been described as chronic inflammatory states. Foot complications are 
frequently treated with prosthetic devices that increase the energy costs of walking and could 
precipitate cardiovascular events in patients with multiple comorbid conditions (20).
For these same reasons, we were surprised that all foot complications were not 
independently associated with mortality. Although CN and DFU frequently precede LEA, 
we did not find an independent effect of either of these foot complications on mortality. LEA 
was the only foot complication that predicted mortality independent of age, sex, race/
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ethnicity, income, BMI, diabetes treatment, HbA1c, LDL cholesterol, smoking, history of 
diabetic nephropathy, myocardial infarction, congestive heart failure, and peripheral vascular 
disease. This may reflect the very high perioperative mortality rate associated with LEA. 
The 30-day mortality after major amputation has been reported to be as high as 16% in 
patients on dialysis (21). Our study confirms that diabetes-related LEAs are associated with 
high 5 and 10-year mortality rates (5, 22–24). The unadjusted 5-year mortality rate for those 
with LEA was 39% and the 10-year mortality rate was 67%. This is higher than the 5-year 
and 10-year mortality rates for those with breast cancer (10% and 17% respectively) and is 
comparable to the 36% 5-year mortality rate, and higher than the 42% 10-year mortality rate 
for those with colorectal cancer (25–26).
Historically, mortality rates after LEA have been reported to be very high. In a study by 
Whitehouse et al., 64% mortality was observed at 5 years for patients who underwent below 
the knee amputation between 1956 and 1965 (27). In our study, 5-year mortality was 39%, 
similar to the 5 year mortality rate for people 40 to 64 years of age with type 2 diabetes after 
amputation and lower than the mortality rate for those 65–84 years of age (~70%) in the 
Swedish National Diabetes Registry (28).
Another concerning finding was the five-fold increased hazard for mortality associated with 
LEA in patients of Hispanic ethnicity. As we demonstrated in our prior work, racial 
differences in the odds of having an amputation were attenuated in the TRIAD population 
(17). However, this new finding indicates that there may still be an increased risk of 
mortality associated with LEA in Hispanics. Our finding underscores the potential 
importance of early access to care and risk factor interventions in reducing amputation risk. 
Once an amputation has occurred, access to care and treatment appear to be ineffective in 
preventing death.
This study has some limitations. We used data from people enrolled in managed care plans; 
our results may not be generalizable to those outside of managed care, or even those in 
managed care plans with different levels of access to care or quality of care. Identification of 
foot conditions relied on data recorded for administrative purposes. These data may not 
accurately represent a patient’s clinical status. However, previous studies have demonstrated 
that CN identified by ICD-9 codes can be confirmed by medical records 92% of the time. 
ICD-9 codes have also been shown to have 93% sensitivity and 91% specificity in 
identifying DFU (29–30). Administrative data do not allow for identification of the foot 
affected so we do not know if the conditions were unilateral or bilateral. We did not observe 
an association between LEA and mortality in those reporting smoking in the past year. 
However, due to survey measurement, the dichotomization of smoking may have resulted in 
misclassification and biased the results of our analysis. Lastly, while we had 6,692 patients 
in our sample, there were only 55 with Charcot feet which limited the power for multivariate 
analyses. It is important to keep in mind, however, that Charcot foot is a relatively rare 
complication of diabetes with an estimated prevalence of 0.1% to 0.9%, so our prevalence of 
1% was actually quite high (31–32).
Early detection of feet at risk and appropriate management are the most important factors in 
preventing diabetes-related foot complications. In our study of managed care patients with 
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access to high-quality health care, we found that LEA remained a robust independent 
predictor of mortality and that the 5 and 10-year mortality rates were high. While our 
previous study noted an attenuation of the racial/ethnic differences in the prevalence of foot 
complications reported in the literature (12), we now observed some differences in the 
association between LEA and mortality by sex and racial/ethnic group with men and 
Hispanics having the highest risk. This suggests that although early treatment and preventive 
care maybe critical for the prevention of foot complications in people with diabetes, LEA 
reflects suboptimal long-term treatment and remains a robust risk factor for mortality.
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Novelty
• In a managed care population with access to high quality medical care, 
lower extremity amputation (LEA) was a robust independent predictor 
of all-cause mortality.
• In this population with good access to high-quality care, the effect of 
LEA on mortality differed by sex and race/ethnicity.
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Figure 1. 
Unadjusted survival curve for TRIAD participants with no lower extremity amputation, 
versus any lower extremity amputation over 10 years.
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Figure 2. 
Unadjusted survival curve for TRIAD participants with no lower extremity amputation, 
minor lower extremity amputation only, and major lower extremity amputation over 10 
years.
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Table 1
Characteristics of the study population using baseline characteristics and mortality data ascertained from 
National Death Index 2000–2009.
Total sample Dead Alive pvalue
N 6992 1956 5036
Age, years (missing=2) 61 ± 13 69 ± 11 59 ± 13 <0.0001
Male sex 3188 (46%) 1003 (51%) 2185 (43%) <0.0001
Race/ethnicity (missing=298) <0.0001
 Hispanic 1250 (19%) 304 (16%) 946 (20%)
 African American 1373 (21%) 373 (20%) 1000 (21%)
 Non-Hispanic White 3395 (51%) 1056 (57%) 2339 (48%)
 Other 676 (10%) 129 (7%) 547 (11%)
Education (missing=110) <0.0001
 Some high school or less 1800 (26%) 686 (36%) 1114 (22%)
 High school degree 1921 (28%) 513 (38%) 1390 (28%)
 Some college 1927 (28%) 452 (24%) 1475 (30%)
 College degree or higher 1234 (18%) 247 (13%) 987 (20%)
Annual income (missing=735) <0.0001
 <$15,000 2106 (34%) 790 (47%) 1316 (29%)
 $15,000–40,000 1902 (30%) 549 (33%) 1353 (30%)
 $40,000–75,000 1411 (23%) 256 (15%) 1155 (25%)
 >$75,000 838 (13%) 89 (5%) 749 (16%)
Type of diabetes (missing=380) <0.0001
 Type 1 362 (5%) 53 (3%) 309 (6%)
 Type 2 6250 (95%) 1749 (97%) 4501 (94%)
Duration of diabetes, years (missing=380) 12 ± 10 15 ± 11 11 ± 10 <0.0001
Treatment for diabetes <0.0001
 Diet only 479 (7%) 117 (6%) 362 (7%)
 Oral medication only 4204 (60%) 1038 (53%) 3166 (63%)
 Insulin only 1428 (21%) 495 (25%) 933 (19%)
 Insulin and oral medication 881 (13%) 306 (16%) 575 (12%)
HbA1c, % (missing=615) (mmol/mol) 8.0 ± 1.9 (64 ± 21) 7.9 ± 1.9 (63 ± 21) 8.0± 1.8 (64 ± 20) 0.0994
Body Mass Index, kg/m2 (missing=226) <0.0001
 < 25 995 (15%) 348 (18%) 647 (13%)
 25 to < 30 2093 (31%) 599 (32%) 1494 (31%)
 30 to < 40 1864 (28%) 484 (26%) 1380 (28%)
 ≥40 1814 (27%) 452 (24%) 1362 (28%)
Systolic blood pressure, mmHg (missing=361) 137 ± 19 139 ± 20 136 ± 19 <0.0001
LDL cholesterol, mg/dL (missing=1885) 113 ± 34 112 ± 36 114 ± 33 0.1930
Smoking (in past year) (missing=91) 1290 (19%) 398 (21%) 892 (18%) 0.0093
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Total sample Dead Alive pvalue
Health history
 Diabetic retinopathy 1162 (17%) 420 (21%) 742 (15%) <0.0001
 Diabetic nephropathy 871 (12%) 398 (20%) 473 (9%) <0.0001
 Microalbuminuria 537 (8%) 155 (8%) 382 (8%) 0.6328
 Diabetic peripheral neuropathy 1289 (18%) 485 (25%) 804 (16%) <0.0001
 Hypertension 4824 (69%) 1519 (78%) 3305 (66%) <0.0001
 Dyslipidemia 3169 (45%) 895 (46%) 2274 (45%) 0.5881
 Congestive heart failure 742 (11%) 465 (24%) 277 (6%) <0.0001
 Coronary heart disease 1693 (24%) 769 (39%) 924 (18%) <0.0001
 Peripheral vascular disease 741 (11%) 377 (19%) 364 (7%) <0.0001
Charlson comorbidity index (missing=27) <0.0001
 0 or 1 2809 (40%) 415 (21%) 2394 (48%)
 2 or 3 3013 (43%) 884 (45%) 2129 (42%)
 4 or more 1143 (16%) 645 (33%) 498 (10%)
Foot complications
 Charcot foot (missing=306) 55 (1%) 24 (1%) 31 (1%) 0.0048
 Diabetic foot ulcer (missing=156) 205 (3%) 93 (5%) 112 (2%) <0.0001
 Lower extremity amputation (missing=260) 101 (2%) 68 (4%) 33 (1%) <0.0001
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Table 2
Unadjusted and Adjusted Cox Proportional Hazards Models predicting all-cause mortality.
Unadjusted Fully Adjusted*
Charcot foot 1.87 (1.24–2.81) 1.25 (0.72–2.16)
Diabetic foot ulcer 1.93 (1.56–2.39) 1.18 (0.86–1.62)
Lower extremity amputation 3.21 (2.50–4.12) 1.84 (1.28–2.63)
*Adjusted for: age, sex, race/ethnicity, income, diabetes treatment, HbA1c, BMI, LDL cholesterol, smoking, and history of congestive heart failure, 
myocardial infarction, diabetic nephropathy, and peripheral vascular disease.
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Table 3
Adjusted Cox Proportional Hazards Models predicting all-cause mortality stratified by age, sex, race/ethnicity, 
and smoking.
Lower extremity amputation
Age
 <45 16.55 (1.45–188.86)
 45–64 1.84 (1.02–3.34)
 ≥ 65 1.80 (1.09–2.97)
Sex
 Male 1.96 (1.25–3.07)
 Female 1.05 (0.50–2.22)
Race/ethnicity
 Hispanic 5.17 (1.48–18.01)
 Black 1.22 (0.51–2.93)
 Other 0.55 (0.06–5.09)
 White 2.18 (1.37–3.47)
Smoking (in past year)
 Not at all 2.27 (1.52–3.39)
 Some or everyday 1.92 (0.72–5.16)
*Adjusted for: age, sex, race/ethnicity, income, diabetes treatment, HbA1c, BMI, LDL cholesterol, smoking, and history of congestive heart failure, 
myocardial infarction, diabetic nephropathy, and peripheral vascular disease.. Note: the model stratified by age is not adjusted for age, the model 
stratified by sex is not adjusted for sex, etc.
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